KYMR
Kymera Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jun 12 FDA: Kymera Therapeutics Presents Phase 1 Data in Healthy Japan…
- Jun 26 ▼ Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P…
- Jun 26 ▼ A significant insider selling cluster at Kymera Therapeutics, led by…
- Jun 26 ▼ BVF Partners L.P./IL, an affiliate of a Kymera Therapeutics director…
- Jun 29 to Jul 7 ▼ 4 days of insider sells: $35.4M by 4 insiders, avg $113.43
- Jul 2 ▼ Kymera Therapeutics (KYMR) saw a massive insider selling cluster ove…
- Aug 5 ▲ Kymera Therapeutics reported Q2 2026 collaboration revenue of $65.0M…
- Sep 4 ▼ 1 insider sell $744.3K at $116.83
- Sep 30 ▲ 3 funds open new positions (13F)
- Oct 1 ▼ 1 insider sell $3.4M at $113.80
- Oct 9 Raymond James initiates
- Oct 28 FDA: Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Vol…
Signal stack
Where each data set points today.
- InsidersBEARISH
5 insiders sold $39.5M.
- InstitutionsBULLISH
Q3 2026: 31 added (3 new), 10 trimmed or exited. Largest new: Capital World Investors $24.9M, Fiera Capital $13.3M.
- AnalystsBULLISH
27 of 30 rate it Buy or better. Median target $144.00 (+14%).
- EstimatesFALLING
Current-quarter EPS estimate −$1.029 → −$1.286 over 90 days. 4 up, 6 down in 30 days.
- Short sellersSTEADY
Short interest −8.4% to 8.40M shares. 10.5 days to cover, ≈9.8% of shares.
- TrendUPTREND
7% above its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 30.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| MORGAN STANLEY | ADD | $40.2M |
| Fisher Asset Management, LLC | DOUBLED | $36.1M |
| Connor, Clark & Lunn Investment Management Ltd. | ADD | $26.1M |
| Capital World Investors | NEW | $24.9M |
| CITIGROUP INC | ADD | $14.2M |
| Fiera Capital Corp | NEW | $13.3M |
| FIRST TRUST ADVISORS LP | ADD | $12.7M |
| Invesco Ltd. | ADD | $11.5M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
30 analystsPrice is inside the target range. Median implies +14%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 2, 2026 | Barclays MAINTAIN | Overweight |
| Oct 30, 2026 | Truist Securities REITERATE | Buy |
| Oct 30, 2026 | RBC Capital MAINTAIN | Sector Perform |
| Oct 29, 2026 | BTIG MAINTAIN | Buy |
| Oct 27, 2026 | Morgan Stanley MAINTAIN | Overweight |
| Oct 9, 2026 | Raymond James INITIATE | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Mainolfi Nello Chief Executive Officer Oct 1, 2026 | SELL | $869.8K |
Mainolfi Nello Chief Executive Officer Oct 1, 2026 | SELL | $949.7K |
Mainolfi Nello Chief Executive Officer Oct 1, 2026 | SELL | $619.0K |
Mainolfi Nello Chief Executive Officer Oct 1, 2026 | SELL | $392.8K |
Mainolfi Nello Chief Executive Officer Oct 1, 2026 | EXERCISE | $62.4K |
Mainolfi Nello Chief Executive Officer Oct 1, 2026 | SELL | $552.2K |
Mainolfi Nello Chief Executive Officer Oct 1, 2026 | SELL | $30.4K |
Adams Brian Chief Legal Officer Sep 4, 2026 | SELL | $139.7K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$1.29 | -$1.54–-$0.78 | -0.9% | $62.5K |
| Next Q | -$1.35 | -$1.52–-$1.08 | +0.9% | $7.0M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | -$5.12 | -$6.70–-$3.36 | -0.4% | $42.0M |
Short side
FINRA· Oct 30, 2026SecBot reports
32 filings · 5 press releases · 2 bullish · 10 bearish · 2 mixed · 18 neutral- NEUTRAL INST-CLUSTERNov 2, 2026
Five institutional asset managers added to their Kymera Therapeutics positions in Q3 2026, with…
The cluster is small in dollar terms and lacks insider corroboration, but the unanimous buying by asset managers may reflect growing conviction ahead of the KT-621 Phase 2b readout due by year-end…
- NEUTRAL 8-KOct 29, 2026
Kymera Therapeutics reported Q3 2026 results with no collaboration revenue ($0 vs $2.8M in Q3…
The key near-term catalyst is the KT-621 BROADEN2 Phase 2b AD topline data expected by year-end 2026, which will be the first efficacy readout for the STAT6 degrader program. The KT-579 Phase 1 data…
- BEARISH PRESS-RELEASEOct 29, 2026
Kymera reported Q3 2026 net loss of $132.0M ($1.32 per share) vs. consensus EPS of -$1.27, a miss…
The EPS and revenue miss are offset by strong cash position and upcoming catalysts: KT-621 Phase 2b AD data by year-end 2026 and KT-579 Phase 1b lupus trial start. Monitor the AD data readout as a…
- NEUTRAL PRESS RELEASEOct 28, 2026
Kymera Therapeutics announced it will present Phase 1 clinical trial results for KT-579, a…
The Phase 1 data release tomorrow will be the first clinical proof-of-concept for KT-579. Positive safety and biomarker data could validate the IRF5 degradation platform and expand Kymera's pipeline…
All KYMR filing & press-release reports (37)
- INST-CLUSTER reportNov 2, 2026
- 8-K reportOct 29, 2026
- PRESS-RELEASE reportOct 29, 2026
- PRESS-RELEASE reportOct 28, 2026
- INST-CLUSTER reportOct 27, 2026
- SC 13G/A reportOct 27, 2026
- PRESS-RELEASE reportOct 22, 2026
- 8-K reportAug 5, 2026
- CLUSTER reportJul 7, 2026
- 144 reportJun 24, 2026
- 144 reportJun 26, 2026
- 144 reportJun 29, 2026
- 144 reportJun 30, 2026
- CLUSTER reportJul 2, 2026
- CLUSTER reportJul 2, 2026
- CLUSTER reportJun 26, 2026
- 144 reportJun 26, 2026
- CLUSTER reportJun 22, 2026
- 144 reportJun 17, 2026
- PRESS-RELEASE reportJun 12, 2026
- INST-CLUSTER reportJun 11, 2026
- INST-CLUSTER reportJun 11, 2026
- PRESS-RELEASE reportJun 8, 2026
- 144 reportMay 26, 2026
- PRESS-RELEASE reportMay 15, 2026
- 144 reportMay 11, 2026
- CLUSTER reportApr 15, 2026
- PRESS-RELEASE reportApr 23, 2026
- CLUSTER reportApr 10, 2026
- 144 reportApr 15, 2026
- 144 reportApr 15, 2026
- 144 reportApr 1, 2026
- 144 reportApr 1, 2026
- PRESS-RELEASE reportMar 28, 2026
- CLUSTER reportMar 20, 2026
- 8-K reportFeb 26, 2026
- 8-K reportFeb 26, 2026